Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15249 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Nadia Fida and 15 co-authors. Institution: Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Heart Transplantation, Plasma Cells. Cited 6 times so far (Crossref); 15 references.
Abstract (original language)
Background
Desensitization is one of the strategies to reduce antibodies and facilitate heart transplantation in highly sensitized patients. We describe our center's desensitization experience with combination of plasma cell (PC) depletion therapy (with proteasome inhibitor or daratumumab) and costimulation blockade (with belatacept).
Methods
We reviewed five highly sensitized patients who underwent desensitization therapy with plasma cell depletion and costimulation blockade. We evaluated the response to therapy by measuring the changes in cPRA, average MFI, and number of positive beads > 5000MFI.
Results
Five patients, mean age of 56 (37‐66) years with average cPRA of 98% at 5000 MFI underwent desensitization therapy. After desensitization, mean cPRA decreased from 98% to 70% ( p = .09), average number of beads > 5000 MFI decreased from 59 to 37 ( p = .15), and average MFI of beads > 5000 MFI decreased from 16713 to 13074 ( p = .26).
Conclusion
Combined PC depletion and CoB could be a reasonable strategy for sustained reduction in antibodies in highly sensitized patients being listed for heart transplantation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA.
- Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA.
- Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
- Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
ORCID profiles: Nadia Fida, Duc T Nguyen
Cite
APA
Fida, N., Eagar, T. N., Yun, A. N., Rogers, A. W., Nguyen, D. T., Graviss, E. A., Ishaq, F., DiPaola, N. R., Kim, J., Janardhana, G., Kassi, M., Yousefzai, R., Suarez, E. E., Bhimaraj, A., Krisl, J. C., & Guha, A. (2024). Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates. Clinical Transplantation. https://doi.org/10.1111/ctr.15249
Vancouver
Fida N, Eagar TN, Yun AN, Rogers AW, Nguyen DT, Graviss EA, et al. Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates. Clinical Transplantation. 2024. doi:10.1111/ctr.15249
BibTeX
@article{Fida2024,
author = {Fida, Nadia and Eagar, Todd N and Yun, Allison N and Rogers, Alex W and Nguyen, Duc T and Graviss, Edward A and Ishaq, Farhan and DiPaola, Nicholas R and Kim, Ju and Janardhana, Gorthi and Kassi, Mahwash and Yousefzai, Rayan and Suarez, Eric E and Bhimaraj, Arvind and Krisl, Jill C and Guha, Ashrith},
title = {Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15249}
}
EUVIMED